Andrew Combs, Chief Chemistry Officer at Prelude Therapeutics Inc. ($PRLD), bought common shares on the open market once in the last year, totaling $69,250. His most recent purchase occurred on March 25, 2025. These buys rank 2,704th out of 4,983 insiders by amount, below the average of $1.46 million across 3.29 transactions per insider. Combs reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 4, 2026 | Prelude Therapeutics Inc | $PRLD | Combs Andrew | Chief Chemistry Officer | A | Employee Stock Option (right to buy) | 230000 | $0.00 | 230,000.0000 | 76,132,337 | 9999.99% | 0.30% |
| March 25, 2025 | Prelude Therapeutics Inc | $PRLD | Combs Andrew | Chief Chemistry Officer | P | Common Stock | 100000 | $0.69 | 480,123.0000 | 75,805,840 | 26.31% | 0.13% |
| Feb. 4, 2025 | Prelude Therapeutics Inc | $PRLD | Combs Andrew | Chief Chemistry Officer | A | Employee Stock Option (right to buy) | 175000 | $0.00 | 175,000.0000 | 75,805,840 | 9999.99% | 0.23% |
| Dec. 20, 2024 | Prelude Therapeutics Inc | $PRLD | Combs Andrew | Chief Chemistry Officer | P | Common Stock | 3075 | $1.15 | 317,623.0000 | 75,855,949 | 0.98% | 0.00% |
| Dec. 23, 2024 | Prelude Therapeutics Inc | $PRLD | Combs Andrew | Chief Chemistry Officer | P | Common Stock | 60000 | $1.37 | 377,623.0000 | 75,855,949 | 18.89% | 0.08% |
| March 1, 2024 | Prelude Therapeutics Inc | $PRLD | Combs Andrew | Chief Chemistry Officer | A | Employee Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 60,357,052 | 9999.99% | 0.25% |